Inhibitors of the complement system currently in development for cardiovascular disease

Author： Pugsley M.   Abramova M.   Cole T.   Yang X.   Ammons W.  

Publisher： Humana Press, Inc

ISSN： 1530-7905

Source： Cardiovascular Toxicology, Vol.3, Iss.1, 2003-03, pp. : 43-69

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease

By  

Current Vascular Pharmacology, Vol. 1, Iss. 3, 2003-10 ,pp. : 301-313

Bentham Science Publishers

Access to resources Recommend Favorite

The Therapeutic Potential of PhospholipaseA2 Inhibitors in Cardiovascular Disease

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 5, Iss. 1, 2007-01 ,pp. : 91-95

Bentham Science Publishers

Access to resources Recommend Favorite

The Renin-Angiotensin System and Cardiovascular Disease

By HOLLENBERG NORMAN K.  

Blood Pressure, Vol. 9, Iss. 1, 2000-05 ,pp. : 5-8

Informa Healthcare

Access to resources Recommend Favorite

Electroencephalography Is a Good Complement to Currently Established Dementia Biomarkers

By  

Dementia and Geriatric Cognitive Disorders, Vol. 42, Iss. 1-2, 2016-09 ,pp. : 80-92

Karger

Access to resources Recommend Favorite

Influence of Chronic Kidney Disease Development and Renin-angiotensin System Inhibition on Cardiovascular Prognosis

By  

Current Medicinal Chemistry - Cardiovascular & Hematological Agents, Vol. 3, Iss. 1, 2005-01 ,pp. : 55-60

Bentham Science Publishers

Access to resources Recommend Favorite